PFIZER TO PRESENT NEW DATA ON INVESTIGATIONAL TOFACITINIB AT THE 11TH CONGRESS OF ECCO

Pfizer Inc announced today that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn’s disease will be presented at the 11th Congress of ECCO, which will be held March 16-19 in Amsterdam, The Netherlands. Among the abstracts are detailed results from two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program. Tofacitinib is being studied as an investigational treatment for adult patients with moderate to severe active UC.

The full list of abstracts to be presented at the 11th Congress of ECCO follows:

Ulcerative Colitis

1. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials (OP019, Friday, March 18, 15:40 - 15:50)

2. Improvement in patient-reported outcomes in two phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis (P369, Friday, March 18, 12:20 - 13:20)

3. Tofacitinib plasma concentration monitoring is not needed for optimization of induction therapy in moderate to severe ulcerative colitis: results of pooled exposure-response analyses of phase 3 induction studies (DOP071, Friday, March 18, 18:54 - 19:01)

Crohn’s Disease

4. Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn’s disease: results of a phase 2b randomized placebo-controlled trial (OP021, Friday, March 18, 17:10 - 17:20)

5. Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate to severe Crohn’s disease: results of a phase 2b randomized placebo-controlled trial (OP022, Friday, March 18, 17:20 - 17:30)

6. Effects of oral tofacitinib on patient-reported outcomes in patients with moderate to severe Crohn’s disease: results of two phase 2b randomized placebo-controlled trials (DOP053, Friday, March 18, 18:54 - 19:01)

7. Tofacitinib pharmacokinetics and durability of drug exposure in moderate to severe Crohn’s disease patients in phase 2 induction and maintenance studies (P428, Friday, March 18, 12:20 - 13:20)